#United States #South San Francisco #3T Biosciences #Marvin Gee #Barbara Sennino

Leadership Changes at 3T Biosciences

In a bold move to strengthen its position in the immunotherapy market, 3T Biosciences has announced the promotion of Dr. Marvin Gee to Chief Research Officer and the appointment of Dr. Barbara Sennino as Senior Vice President and Head of Early Development. These two key leadership roles are designed to catalyze the company’s efforts in pioneering T-cell receptor (TCR)-based therapeutics, particularly aimed at treating solid tumors and various immune-mediated diseases.

The New Leadership at 3T Biosciences

Dr. Marvin Gee has been a critical figure in the development of 3T’s research strategies since its inception. His promotion acknowledges his significant contributions, where he previously served as Vice President and Head of Research. Under his guidance, 3T has made substantial progress in its innovative research platforms such as 3T-TRACE™ and 3T-PRIME™, which focus on unlocking the potential of TCR therapies.

In his new role, Dr. Gee expresses his enthusiasm: "I'm honored to take on this new role at 3T as we continue to push the boundaries of TCR-based therapies for solid tumors. Our platform is designed to unlock new therapeutic opportunities, and I look forward to working with our exceptional team to advance our pipeline toward the clinic and, ultimately, to patients in need."

On the other hand, Dr. Barbara Sennino, a seasoned expert in the field of cancer immunotherapy, brings over 15 years of experience to her new position. Prior to this role, she was Vice President of Immunotherapy at Turnstone Biologics, where she oversaw the preclinical development of tumor-infiltrating lymphocytes. Dr. Sennino's wealth of knowledge and experience in early-stage development is expected to be invaluable to 3T as they strategize for the clinical evaluation of their therapeutic candidates.

Dr. Sennino looks forward to her new challenges, stating, "3T's innovative approach to TCR-based immunotherapy has the potential to transform the treatment landscape for solid tumors. I'm excited to join the company at this critical time and contribute to the translation of our cutting-edge science into impactful therapies for patients."

The Future of 3T Biosciences

As 3T Biosciences continues to advance its pipeline, the company’s focus remains squarely on developing next-generation therapies that hold the potential for curative outcomes. The recent appointments not only aim to enhance the scientific and translational expertise within the firm but also to prepare for potential clinical trials and the introduction of new therapies to the market. The company's commitment to innovative treatment solutions is further underscored by its strong financial backing from prominent investors, including Westlake Village BioPartners and Lightspeed Venture Partners.

With the leadership of experts like Dr. Gee and Dr. Sennino, 3T Biosciences is well-positioned to navigate the complexities of the biopharmaceutical landscape and make significant strides in immunotherapy development. As they continue to explore the promising avenues of TCR-based therapies, their efforts could lead to groundbreaking advancements in the treatment of solid tumors, bringing hope to countless patients in need of effective treatment options.

In conclusion, the strategic realignment of leadership at 3T Biosciences marks a pivotal moment in the company's journey. As they gear up for the exciting challenges ahead, both Dr. Gee and Dr. Sennino are set to play instrumental roles in steering the company toward its ambitious goals.

About 3T Biosciences

Founded to discover and develop transformative immunotherapeutics, 3T Biosciences leverages its proprietary platforms to innovate solutions in the fight against cancer. With a robust pipeline and a dedicated team, 3T is poised to make meaningful contributions to immunotherapy, driven by a commitment to scientific excellence and patient-centered outcomes.